Actively Recruiting
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Led by M.D. Anderson Cancer Center · Updated on 2026-04-14
70
Participants Needed
1
Research Sites
326 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stem cells (MSC). The purpose of the phase II trial is to compare the effect of MSC with standard of care in these patients. MSCs are a type of stem cells that can be taken from umbilical cord blood and grown into many different cell types that can be used to treat cancer and other diseases. The MSCs being used for infusion in this trial are collected from healthy, unrelated donors and are stored and grown in a laboratory. Giving MSC infusions may help control the symptoms of COVID-19 related ARDS.
CONDITIONS
Official Title
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than or equal 18 years.
- Chest x-ray findings concerning for pneumonia from any cause, with clinical signs suggestive of at least moderate illness such as respiratory rate >20 breaths per minute or oxygen saturation less than 93% on room air.
- COVID-19 associated pneumonia classified as moderate, severe or critical according to FDA guidance.
- Negative pregnancy test in women with childbearing potential.
- Participant or legally authorized representative consent.
- Participants previously enrolled in other IND trials for cancer or COVID-19 are eligible.
You will not qualify if you...
- Moribund participants not expected to survive up to 48 hours.
- Participants with severe chronic liver disease (Childs-Pugh score > 10).
- Pregnant and/or lactating women.
- Participants on extracorporeal membrane oxygenation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
B
Bethany Overman
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here